New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 10, 2014
08:50 EDTKERXKeryx announces submission of MAA for Zerenex to EMA
Keryx Biopharmaceuticals announced it has submitted a Marketing Authorization Application, or MAA, to the European Medicines Agency, or EMA, seeking the approval of Zerenex as a treatment for hyperphosphatemia in patients with chronic kidney disease, or CKD, including dialysis- and non-dialysis dependent CKD. The MAA will be reviewed by the EMA Committee for Medicinal Products for Human Use and the review will be conducted under the Centralized Authorization Procedure. An approval under the Centralized Authorization Procedure provides one marketing authorization which is valid in all 27 member states of the European Union, as well as in Norway, Liechtenstein and Iceland.
News For KERX From The Last 14 Days
Check below for free stories on KERX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 11, 2014
11:07 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
09:57 EDTKERXSummer Street chief scientific officer holds an analyst/industry conference call
Subscribe for More Information
September 10, 2014
11:22 EDTKERXOptions with decreasing implied volatility
Subscribe for More Information
September 9, 2014
12:02 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CIEN FNSR PAY BKS PVH NAV BYI FTR JOY
September 8, 2014
16:18 EDTKERXOn The Fly: Closing Wrap
Subscribe for More Information
10:42 EDTKERXOptions with decreasing implied volatility
Options with decreasing implied volatility: KERX CONN CIEN INSM FNSR PAY PVH SWY
10:06 EDTKERXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:29 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital
Subscribe for More Information
09:18 EDTKERXKeryx price target raised to $32 from $30 at Roth Capital
Subscribe for More Information
09:12 EDTKERXOn The Fly: Pre-market Movers
Subscribe for More Information
07:38 EDTKERXKeryx label for ferric citrate incrementally negative, says JPMorgan
JPMorgan says the approved label for Keryx's ferric citrate is incrementally negative given the lack of clear articulation of ESA/IV iron sparing data. The firm keeps an Overweight rating on the stock with a $24 price target, saying Keryx's 2024 patents are strong.
06:26 EDTKERXKeryx downgraded to Underperform from Market Perform at FBR Capital

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use